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Intrarenally synthesized angiotensin II (Ang II) may be
involved in the progression of glomerulonephritis, leading to
irreversible glomerulosclerosis. There is increasing evidence
that systemic angiotensin receptor blocker (ARB) treatment
has beneficial effect on the prognosis of progressive
glomerulonephritis and diabetic nephropathy. However, the
cellular and molecular mechanisms behind this therapeutic
effect of ARB remain unclear. In this study, we used a novel
strategy of local ARB delivery via type-1 collagen sponge, to
treat progressive glomerulonephritis that would result in
irreversible glomerulosclerosis in our previously established
rat model. At days 9 and 14 after disease induction, mild
proteinuria, 20.774.7 and 1071.3 mg/day, was found. Local
ARB treatment reduced proteinuria significantly to 3.1973.2
and 5.2570.95 mg/day (Po0.01), respectively. Scoring of
glomerular matrix expansion and sclerotic index revealed
that local ARB treatment significantly ameliorated glomerular
pathology. Ang II type 1 receptor mRNA expression was
remarkably enhanced in the Ang II group and ARB treatment
reversed this effect at 14 days. Local delivery of ARB
significantly improved glomerular blood flow levels,
compared to the untreated disease control group, from
710718.25 to 859.44722.86 lm/s, respectively. Local
delivery of ARB into the kidney affected local RAS and thus
improved the renal injury and function in the potentially
progressive glomerulosclerosis of rat model.
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Angiotensin II (Ang II) triggers cell proliferation and
accumulation of extracellular matrix through its type 1
receptor (AT1), leading to glomerulosclerosis.1–2 Recently, we
described an experimental model for analyzing the patho-
genesis of progressive glomerulosclerosis, induced by
unilateral nephrectomy following mesangial cell injury by
anti-Thy-1 antibody (Ab) injection (one kidney model).3,4 In
comparison with the reversible two-kidney model (conven-
tional anti-Thy-1 model), the regeneration of glomerular
endothelial cells was remarkably suppressed, leading to
irreversible glomerulosclerosis with renal insufficiency. Me-
chanisms underlying progressive glomerulosclerosis could
include disturbed glomerular hemodynamics, growth pro-
motion, and profibrotic effects of the renin angiotensin
system (RAS). In recent clinical and experimental studies,
performed in our and other laboratories, the inhibition of
RAS with Ang-converting enzymes or angiotensin receptor
blockers (ARBs) was shown to attenuate glomerular damage
by improving both hemodynamic and non-hemodynamic
parameters, such as angiogenesis, vascular remodeling, intra-
glomerular red blood cell (RBC) velocity, and glomerular
blood volume.5–12
Many investigators have attempted to block the effect of
RAS with systemic use of ARB or Ang-converting enzymes as
a therapeutic approach to treat both secondary glomerular
disease, such as diabetic nephropathy, and primary glomeru-
lar diseases.13–16 These results allowed us to predict the
underlying pathomechanisms induced by local action of RAS.
The unusual local expression of Ang II in renal interstitial
cells is probably related to pathogenic mechanisms involved
in progressive glomerulonephritis.17–20 Therefore, local
blockade of Ang II action could be an effective strategy to
halt or ameliorate progressive glomerulonephritis. Very
recently,21 in our model, we demonstrated that the temporal
turning point determining the progression of glomerulo-
nephritis to irreversible glomerulosclerosis seemed to occur
7–14 days after disease induction. This prompted us to
investigate the significance of the local RAS in injured kidney
and the effect of local blockade of RAS at day 7, using our
novel approach of renal subcapsular implantation of collagen
sponge combined with ARB.
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RESULTS
Effects of renal local drug delivery system in untreated,
uninephrectomized rats and anti-Thy-1-treated rats followed
by unilateral nephrectomy
As shown in Figure 1, after unilateral nephrectomy and
implantation of collagen sponge in normal rats (Nx), there
was a slight increase in urinary protein excretion in the
NxþAng II group (6.3371.5 mg/day) compared to the Nxþ
(phosphate-buffered saline) PBS-control group (1.7570.5 mg/
day) at day 9 (Po0.01). Combination of ARB with Ang II
reversed this enhanced excretion of urinary protein compared
to the NxþAng II group. The urinary protein level of
NxþARB group was similar to that of Nxþ PBS-control
group (data not shown).
Anti-Thy-1 glomerunephritis with unilateral nephrectomy
was treated by implantation of collagen sponge containing
Ang II, Ang IIþARB, and PBS. At day 9 in the Nxþ anti-
Thy-1.1 antibody (ATS)þ PBS group, urinary protein
excretion was 20.772.2 mg/day. ARB treatment significantly
decreased urinary protein excretion to 3.1973.2 mg/day,
representing normal levels (Po0.01), proteinuria in
NxþATSþAng II group, 25.6774.7 mg/day appeared to
be higher than that of the NxþATS group, and to be
reversed by combination with ARB, 20.0270.87 mg/day at
day 9. At day 14, urinary protein excretion in
NxþATSþAng II group was also higher, at 48.279.1 mg/
day, compared to a urinary excretion of 1071.3 mg/day in
the NxþATS group. Combined treatment with Ang II and
ARB also reduced proteinuria, 32.772.1 mg/day. Single ARB
treatment significantly decreased the urinary protein excre-
tion to 5.2570.9 mg/day (Figure 1).
At days 9 and 14 after disease induction, there were no
significant differences in the serum total protein, total
cholesterol, blood urea nitrogen, albumin, and creatinine in
NxþATS, NxþATSþAng II, NxþATSþAng IIþARB,
and NxþATSþARB groups (Table 1). Left kidney weight/
body weight in the NxþATSþAng II, NxþATSþAng
IIþARB, NxþATSþARB, and NxþATS groups mani-
fested similar values with no significant differences (Table 2).
There were no significant differences between the
NxþAng II, NxþAng IIþARB, Nxþ PBS, and NxþARB
groups using Nx with unilateral nephrectomy in respect of
mean arterial pressures (Table 2), suggesting that a locally
administrated dose might have a much lower effect on
systemic blood pressure.
Next, we examined the expression of AT1 in glomeruli by
immunofluoresence to evaluate the local action of ARB.
There was no apparent changes of AT1 expression in the
untreated, NxþATS rats and NxþATS rats treated with
ARB at day 14, respectively (Figure 2a and b), whereas IF-
intensity of AT1 staining appeared to be increased slightly
compared to Nx group (Figure 2e). In contrast, AT1
expression was initially remarkably enhanced in the
NxþATSþAng II group (Figure 2c) and then could be
reversed by administration of ARB down to the level of the
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Figure 1 | Urinary protein excretion in Nx and NxþATS rats.
Urinary protein excretion in rats was determined in 24 h urinary
specimens 9 and 14 days after injection of 1-22-3 Ab. Data are
expressed as mean values7s.d.; ##Po0.01 vs Nx rats at day 9,
**Po0.01 at day 9 vs NxþATS and zzPo0.01 vs NxþATS at
day 14. (N¼ 12).
Table 1 | Serum biochemical analysis of Nx+ATS rats
N=12 TP (g/dl) Alb (g/dl) TC (mg/dl) BUN (mg/dl) Cr (mg/dl)
DC
9 day 5.770.8 3.370.4 79.2710.1 32.7720.6 0.370.04
14 day 5.170.7 3.270.4 77.879.34 33.1719.7 0.370.01
Ang II
9 day 5.770.4 3.370.3 87.4710.2 40.774 0.370.03
14 day 5.970.8 3.570.4 88.3712.1 3872.7 0.370.04
A+A
9 day 5.770.9 370.2 83.8716.5 42.278.07 0.370.05
14 day 5.670.8 3.370.5 85713.1 43.1710.2 0.370.04
ARB
9 day 5.770.9 3.670.5 83.9714.4 32.277.3 0.470.1
14 day 5.670.9 3.770.7 84713.9 31.178.2 0.370.02
Alb, albumin; Ang II, angiotensin II; ARB, angiotensin receptor blocker; BUN, blood urea nitrogen; Cr, creatinine; DC, disease control; TC, total cholesterol; TP, total protein.
All rats had unilateral nephrectomy. N, number of rats observed in each group. Each value is expressed as mean7s.d. Data in disease control group (DC: Nx+ATS), Ang II, Ang
II+ARB (A+A), and ARB groups were obtained at days 9 and 14 after Thy-1 antibody injection. P-values of all groups were insignificant vs disease control group.
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Nx group (Figure 2d), at day 14. In addition, we confirmed
the local effect of ARB on renin expression, namely a distinct
difference in renin expression at the juxtaglomerular region
between the NxþATSþARB (Figure 3d) and the other
groups of rats (Figure 3a–c), at day 14.
Improvement of renal histopathology induced by local
delivery of ARB alone, compared to effects of Ang II and
Ang IIþARB, in progressive glomerulonephritis
Light microscopic findings revealed that on day 14 there was
diffuse mesangial cell proliferation and mesangial matrix
expansion in the NxþATS group (Figure 4a). Following Ang
II treatment pathological lesions, such as diffuse mesangio-
lytic changes, exudation into urinary space, adhesion of
glomerular capillary tufts, and often-crescent formation and
expansion of glomerular matrix were seen (Figure 4b). In the
NxþATSþAng IIþARB group and NxþATS groups
(Figure 4a and c), there were also severe glomerular lesions.
In contrast, mesangial cell proliferation in the NxþATSþ
ARB group was significantly decreased, compared to all other
groups (Figure 4d).
Figure 5 shows that the glomerular matrix expansion score
in the NxþATSþAng II group also remained significantly
higher (2.470.5) than in any other group (NxþATSþAng
IIþARB: 1.370.05), (NxþATSþARB: 0.6470.03; Po0.01),
(NxþATS: 1.270.06). Similarly the glomerular sclerotic index
in the NxþATSþAng II group was also significantly higher
(0.8670.16; Po0.01), than in the NxþATSþAng IIþARB
group (0.2570.06), the NxþATSþARB group (0.0670.02;
Po0.01), and NxþATS group (0.270.03) (Figure 6). There
was no significant difference in both mesangial matrix and
sclerosis score of glomeruli localized in the superficial cortex
and in the deep cortex.
There were no marked histological changes in control
(Nx), NxþAng II, NxþAng IIþARB, and NxþARB
groups (Figure 7a–d), at day 14.
Table 2 | General features of experimental rats (day 9)
Nx+ATS (disease
control) ATS+ARB ATS+Ang II
ATS+Ang
II+ARB Nx (control)
Nx+Ang
II+ARB Nx+Ang II Nx+ARB
N=12 — — — — — — — —
Body weight (gm) 121.677.2 123.4713.5 111.474.1 114.876.1 93.3374.2 101.3720.0 124.6675.0 96.273.4
Kidney weight (mg) 972.27130.6 911.0782.3 880.0758.9 743.47290.2 853.475.8 870.0726.4 973.37110.2 84574.5
Kidney weight/body weight
(mg/g)
871.4 7.470.6 7.870.6 6.472.4 9.170.34 8.7671.6 8.670.5 8.970.44
Mean arterial pressure (mm
Hg)
93.674.2 94.473.4 96.674.6 95.373.0 92.774.9 94.4475.6 93.2274.7 93.574.5
RBC velocity (mm/s) 710.1718.2 859.4722.8a 552.2747.2a 730.6763.9 960.37313.7 958.77296.3 947.47243.5 943.37296.7
Blood volume (nl/min) 370.2 370.6 1.170.2a 2.871.4 4.7371.7 4.8672.2 4.8372.31 4.8972.33
Ang II, angiotensin II; ARB, angiotensin receptor blocker; Nx, normal rats; RBC, red blood cell.
All rats had unilateral nephrectomy. N, number of rats observed in each group.
aPo0.01 vs disease control group and each values are expressed as mean7s.d.
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Figure 2 | Immunofluorescent staining in NxþATS rats for
AT1 receptors at day 14. (a) Disease control group (NxþATS),
(b) NxþATSþARB group, (c) NxþATSþAng II group,
(d) NxþATSþAng IIþARB group, and (e) Nx group (original
magnification 400).
a b
c d
Figure 3 | Immunofluorescent double staining in NxþATS rat
for endothelial cells (PECAM-1) and renin cells (renin Ab) at day
14. (a) NxþATS, (b) NxþATSþAng II group, (c) NxþATSþAng
IIþARB group, (d) NxþATSþARB group. FITC-labeled renin
expression was only observed in the NxþATSþARB-treated group
(original magnification 400).
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Expression of Ang II type 1a and Ang II type 1b receptors at
the level of mRNA
In addition, we evaluated AT1a, AT1b, and AT2 mRNA
expression quantitatively, by real-time polymerase chain
reaction (PCR). At day 14, the ratios of AT1a and AT1b
receptor expression to that of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) in the NxþATS groups treated
with ARB were dramatically lower than in other groups
without ARB treatment. Ang II administration remarkably
enhanced AT1a and AT1b expression, whereas there was no
marked change in AT2 expression at day 14 (Figure 8).
Real-time observation of glomerular microcirculation
To evaluate the integrated vascular function of the micro-
circulation, at day 9 after disease induction, we examined
real-time glomerular blood flow by confocal laser micro-
scopy. Figure 9 showed a significant decrease in the
RBC velocity in the NxþATSþAng II group (552.277
47.2 mm/s), compared to NxþATSþAng IIþARB
(730.63763.9mm/s), NxþATSþARB (859.44722.86mm/s),
a b
c d
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Figure 4 | Light microscopic findings in anti-Thy-1.1 nephritis rats
(NxþATS) Rats at day 14. (b) In the NxþATSþAng II group, there
was thickening of glomerular basement membrane with severe,
diffuse mesangiolytic changes. Some glomeruli showed crescentic
lesions with increased production of extracellular matrix. (c) In the
NxþATSþAng IIþARB group and (a) NxþATS group, glomerular
lesions were relatively less severe compared to the NxþATSþAng II
group. (d) In the NxþATSþARB group, remarkably mild mesangial
sclerotic lesions with significantly decreased mesangial cell
proliferation were observed compared to all other groups
(bar¼ 50mm).
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Figure 5 | ARB treatment improved glomerular expansion in
NxþATS rats at 14 day. Data are expressed as mean values7s.d.
(N¼ 12). **Po0.01 vs disease control group.
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Figure 6 | ARB treatment improved sclerotic indexes in NxþATS
rats at 14 day. Data are expressed as mean values7s.d. (N¼ 12).
**Po0.01 vs disease control group.
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Figure 7 | Light microscopic findings at day 14 in
uninephrectomized (Nx) rats. (a) Nx group, (b) NxþAng II,
(c) NxþAng IIþARB group, (d) NxþARB (bar¼ 50mm).
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Figure 8 | mRNA expression of Ang II receptors (AT1a, AT1b,
and AT2) in NxþATS rats at day 14 by real-time PCR. The results
are shown as ratios to the mRNA expression of GAPDH. Data are
expressed as mean values7s.d. **Po0.01 vs disease control group.
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and NxþATS group (710718.2 mm/s). This result shows
that ARB treatment significantly enhanced RBC velocity
compared to other groups (Po0.01).
DISCUSSION
Recent clinical studies revealed that substances that block the
renin–Ang–aldosterone system had a beneficial effect on the
progression of glomerulonephritis, that otherwise would lead
to renal death.26–31 ARB is one of the blocking agents of Ang
II, the main effector of the renin–Ang–aldosterone system,
and is now in worldwide use for treatment of systemic
hypertension and/or progressive glomerulosclerosis.
Although the renoprotective effect of ARB is established,
the cellular and molecular mechanisms involved remain to be
clarified. In particular, a renoprotective effect of ARB, beyond
lowering systemic hypertension, attracts attention, as it could
help to clarify the precise mechanisms of progression in
glomerulonephritis mediated by the local renin–Ang–aldo-
sterone system. In an attempt to analyze additional, relevant
pathways, we focused on a rat model of irreversible
glomerulosclerosis, employing novel local delivery of ARB,
by combination with renal subcapsular implantation of type-
1 collagen sponge.
Collagen sponge is a potent biological carrier material that
can be used to deliver bioactive substances in various
pathophysiological settings.32–38 This is the first report on
attempts to deliver ARB to the kidney in combination with
collagen sponge. Our present study showed that local delivery
of Ang II affected urinary protein excretion in both normal
and disease conditions, although the effect of Ang II could be
reversed with combinational implantation of ARB. In
addition, there were no marked effects on systemic blood
pressure or serum chemistry after this local treatment. Of
additional interest was the remarkable enhancement of renin
expression in the juxtaglomerular region, preferentially
localized in proximity to the afferent arterioles, after
treatment by subcapsular implantation with ARB. The precise
mechanisms of enhanced renin secretion at the cellular and
molecular levels are still unclear, but competition of locally
delivered Ang II or ARB with renal AT1 may occur.
Consistent with our findings, there are reports that ARB
treatment prevented Ang II-induced inhibition of renin
release, leading to enhanced intrarenal renin content and
plasma renin activity.39,40
Systemic administration of ARB exerts a great influence
on the renal expression of AT1.40–42 The present study
showed that expression of AT1 receptor, following subcap-
sular implantation with Ang II, was dramatically increased at
both the mRNA and protein levels and furthermore, this
specific reaction was reversed by local delivery of ARB 14 days
after the disease induction.
To evaluate pharmaceutical effects on renal disease, we
selected a suitable experimental model of progressive
glomerulonephritis, leading potentially to irreversible glo-
merulosclerosis. We used the one-kidney model (rat), in
which anti-Thy-1 Ab was injected followed by unilateral
nephrectomy.3,10,21 This model is advantageous, because
when we compared the one- and two-kidney models we
discovered a fundamental difference in disease prognosis,
namely progressive and reversible sclerosis, respectively. In
our recent work of one-kidney rat model21 using the same
experimental schedule of our present study, proteinuria in
disease control rats was the highest (96.7743.1 mg/day) at
day 3 and it came down to 7.575.1 mg/day, at day 14.
Eventually, the proteinuria rose up to 56.6720.0 mg/day at
day 84 leading to irreversible glomerulosclerosis. Although
we have not confirmed the re-worsened level of proteinuria at
days 56 and 84, the glomerular injury induced in the present
study is expected to be progressive glomerulosclerosis at the
late stage.
In ablation models, particularly 5/6 nephrectomy,42
progressive course of glomerulosclerosis with expression of
Ang II and AT1 receptor in the interstitial tissue in the
proximity of the juxtaglomerular region was enhanced in the
advanced stage. Following high dose of ARB administration,
expression of both substances was reversible back to pre-
disease levels. We used real-time PCR for quantitative AT1a,
AT1b, and AT2 mRNA expression to evaluate the inhibition
of the local renin-Ang system by ARB. We found a significant
upregulation of AT1 protein expression in rat glomeruli
following anti-Thy-1 Ab injection, supporting the idea that
injured glomeruli are susceptible to locally acting Ang II,
promoting proliferation and matrix accumulation within the
glomeruli. Moreover, the ratios of AT1a and AT1b receptor
mRNA expression to GAPDH expression in the
NxþATSþAng IIþARB group were 1/3 lower at day 14,
than in the NxþATSþAng II group in anti-Thy-1-treated
rats. Furthermore, immunoflourescent studies showed that
AT1 receptor expression in glomeruli was increased in the
Ang II-treated groups. In contrast, there were significant
differences in expression of AT1a and AT1b in
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Figure 9 | RBC velocity within the glomeruli in NxþATS group
at day 9. Nine days after the disease induction the RBC velocity in
NxþATSþAng II group was significantly reduced, but when
combined with NxþATSþARB the velocity increased, as in the
NxþATS group. There was a significantly increased intraglomerular
erythrocyte velocity in the NxþATSþARB group compared to all
other groups. All data were expressed as means7s.d. **Po0.01 vs
disease control group (N¼ 12).
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NxþATSþAng IIþARB, NxþATSþARB, and disease
control groups. In view of the markedly low expression level
of AT2 in Thy-1 glomeruli found in this study, a contribution
of AT2 to the effects seen appears unlikely.
Accumulative effects of the various pathways involved in
microvascular function are reflected by glomerular hemo-
dynamics, as an integrated vascular function. Using a new
mapping system, it is possible to observe glomerular
microcirculation in vivo,4 and also examine whether delivered
ARB acts on hemodynamic or on the non-hemodynamic
mechanisms that lead to progressive glomerulosclerosis. In
the present study, there was a significant decrease in the
glomerular RBC velocity in the NxþATSþAng II group,
compared to NxþATSþAng IIþARB, NxþATSþARB,
and the untreated, NxþATS groups. The NxþATSþARB
group showed increased RBC velocity compared to all other
groups. In addition, glomerular blood volume was signi-
ficantly decreased in the NxþATSþAng II group, compared
to the other groups.
Our preliminary data (Okada S et al. J Am Soc Nephrol
2004; 15: 212A) showed that mean arterial blood pressure of
carotid artery was 65.375.5 mm Hg when the same ARB was
administrated orally in the Munich Wistar for 4 weeks,
significantly lower than in untreated diseased control,
85.473.8 mm Hg. In contrast, when ARB was delivered
locally into the kidney in our present study did not affect the
systemic blood pressure, although the renoprotective effect
was found at the same level as in the oral administration
of ARB. This result is also consistent with the finding of
Ma et al.43 They made deficient in renal AT1 by using
in vivo renal transfection of antisense oligodeoxynucleotide,
resulting in ameliorating glomerular injury in Thy-1
nephritis, although there was no significant change in systolic
blood pressure. In spontaneously hypertensive rats, selective
renal inhibition of AT1 by the infusion of antisense
oligodeoxynucleotides manifested decreased proteinuria with
improved glomerular pathology, probably resulting from
independent of systemic blood pressure and circulating Ang
II levels.44
Taken together, it is reasonable to consider that ARB,
delivered via renal subcapsular source was able to block local
RAS activity in the kidney, and exerted a potential beneficial
effect on the progression of glomerulonephritis leading to
irreversible glomerulosclerosis. Local delivery of renoprotec-
tive agents, such as ARB, in combination with diagnostic
imaging systems of the renal microvasculature, allowed us to
evaluate the therapeutic effect of local blockade of RAS
activity on the progression of glomerosclerosis leading to
renal death.
MATERIALS AND METHODS
Animals
All animal procedures were conducted after approval by the Animal
Committee of Niigata University. All experiments were performed
using 6- to 8-week-old female Munich Wistar rats, purchased from
Simonsen Laboratories, Gilroy, CA, USA.
Collagen sponge
Type-1 collagen sponge was a kind gift from Professor Y Tabata,
Kyoto University, Japan and was also purchased from Nitta gelatin
Co., Tokyo, Japan.
ARB and Ang II
Valsartan (ARB), a kind gift from Novartis Pharmaceuticals, Basel,
Switzerland was used. Ang II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe)
(acetate salt; human; synthetic) was purchased from Sigma, St Louis,
MO, USA.
Experimental design
Rats were divided into two major groups; anti-Thy-1þ
uninephrectomy (NxþATS) group and only uninephrectomy
group (Nx rats). Rats in the NxþATS group were injected with
1.0 mg of anti-Thy-1.1 (1-22-3 monoclonal antibody) Ab intra-
venously and 30 min after injection unilateral nephrectomy of the
right kidney was performed, to induce progressive glomerulo-
nephritis with irreversible glomerulosclerotic lesions, as described
previously.3,21,22 Seven days after injection, subrenal capsular
implantation of collagen sponge with ARB (Valsartan), Ang II,
Ang IIþARB, and PBS (untreated disease control) was performed.
In Nx rats group, unilateral nephrectomy and subrenal capsular
implantation of collagen sponge Ang II, Ang IIþARB, PBS (drug
control), and ARB were performed. All animals were killed on day 9
or 14 after nephrectomy. The whole kidneys were examined for
glomerular matrix score, mesangial proliferation index, renin
expression, and AT1 expression.
Subrenal capsular implantation
Pellets of type-1 collagen prepared at 10 5 mm2 and 1.5 mm
thickness, weight 50 mg, and were combined with 50 ml of
PBS (disease control), Valsartan (10 mg/ml), Ang II (106 M), and
Ang IIþARB (25ml each), respectively and lyophilized for 1 h
before implantation. Rats were anesthetized by intraperitoneal
injection of thiobutabarbital sodium salt (100 mg/kg) and flank
incision was made on the left side of the abdomen to expose
the left kidney. The renal capsule of the left kidney was elevated and
a small aperture was made by a small spatula. In the subrenal
capsular pocket, collagen sponge was implanted and the
abdominal incision was closed. We observed that 2/3 of the
implanted collagen sponge still remained at the implanted site after
6 weeks without histological signs of inflammation or tissue
rejection around it.
Light microscopy
All ATS rats were killed after 14 days of injection of monoclonal
antibody 1-22-3. As described previously,3 paraffin sections (3 mm
thick) were stained with periodic acid-Schiff and periodic acid
methenamine silver. Using periodic acid-Schiff-stained sections,
mesangial proliferation and glomerular sclerosis were graded
semiquantitatively on a scale of 0 to 4þ .23
Urinary analysis
The amount of urinary protein excreted was determined by the
biuret method.10
Serum biochemical analysis
Serum total protein, serum albumin, total cholesterol, blood urea
nitrogen, and creatinine concentrations were measured.
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Intravital observation of the renal microcirculation
Observation of microcirculation blood flow was made with an
intravital microscope system (Yokogawa Electric Corporation,
Tokyo, Japan), equipped with a real-time confocal scanner unit
model CSU-10 and image processing devices, according to our
previously described methods.3,4
Immunofluorescent microscopy
As described previously,12 frozen sections were incubated with
monoclonal mouse anti-rat PECAM-1 (Serotec Ltd, Kindlington,
UK), goat anti-rat renin (1:1600) Ab (a kind gift from Professor T
Inagami, Vanderbilt University, USA), and rabbit anti-rat AT1
(1:800) Ab (Abcam, Cambridge, UK). Tetramethyl rhodamine B
isothiocyanate-conjugated rabbit anti-mouse immunoglobulin
Ab, fluorescein isothiocyanate-conjugated rabbit anti-goat immu-
noglobulin G Ab, and tetramethyl rhodamine B isothiocyanate-
conjugated goat anti-rabbit immunoglobulin Ab were used as
secondary antibodies (Dako, Denmark). Sections incubated with
PBS or secondary Ab, instead of the primary antibodies, were served
as negative control. Sections were examined with a confocal laser
scanning immunofluorescent microscopy, combined the MRC-1024
confocal imaging system (Bio-Rad Laboratories, Hemel Hempstead,
UK).24
Real-time PCR
Total RNA was extracted from whole kidneys using RNA STAT kit
(Roche Diagnostics, Mannheim, Germany). First strand cDNA was
synthesized according to the manufacturer’s instruction. The cDNAs
were amplified by real-time PCR with primers for rat AT1a
(GenBank Accession-NM_030985), AT1b (GenBank Accession-
X64052), AT2 (GenBank Accession-U22663), and GAPDH (Gen-
Bank Accession-AF106860) as an internal control, using Lightcycler-
Primer/Probes Set of rat AT1a, AT1b, AT2, and GAPDH (Nihon
Gene Research Laboratories Inc., Osaka, Japan). All real-time PCRs
were performed according to the manufacturer’s (Roche Diagnos-
tics) instruction. PCRs quantifications were used a standard curve.25
The ratios of AT1a, AT1b, or AT2 to GAPDH copies were calculated.
Statistical analysis
All values were expressed in the form mean7s.d. The Student’s
unpaired t-test was used for comparison of urinary protein
excretion and serum biochemical analysis. Analysis of variance in
combination with Bonferroni test was used for multiple compar-
isons. All data analysis was performed using Kyplot software. A
P-value less than 0.05 was considered significant in all statistical tests.
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